Company Focus
Novartis
Latest Novartis News
Pharmaceutical
Under the Medicare Drug Price Negotiation Program (Negotiation Program), the US Centers for Medicare & Medicaid Services (CMS) directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. 16 March 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Purple Biotech focuses on immuno-oncology and targeted cancer therapies designed to enhance immune responses against solid tumors.
Latest News & Features of interest to Novartis
Pharmaceutical
armaceutical Development & Commercialization and its parent Japan-based Otsuka Pharmaceutical have announced new open-label extension study data for repinatrabit (JNT-517), demonstrating early and clinically-meaningful reductions in blood phenylalanine (Phe) levels (-67% mean change from baseline) in adolescents with phenylketonuria (PKU).
13, 2026 13 March 2026
Biotechnology
Israeli clinical-stage drug developer Purple Biotech today announced that its chief executive, Gil Efron, will step down from his role as CEO effective August 2026. 13 March 2026
Biosimilars
Spanish biologics CDMO 3PBIOVIAN has signed an agreement with Colombia’s National Cancer Institute to develop a biosimilar monoclonal antibody for an oncology indication, in a program aimed at expanding access to cancer medicines in the country. 13 March 2026
Pharmaceutical
Chinese radiopharmaceutical startup Eli Radiopharma has secured around 100 million yuan ($14.5 million) in fresh financing as it expands its pipeline and deepens industry partnerships. The Hangzhou-based company said the funds will support target discovery, platform development and clinical translation across oncology and neurological disease programs. 13 March 2026
Pharmaceutical
Japan’s PRISM BioLab and USA-based Receptor.AI Inc have entered into a drug discovery collaboration agreement to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems. 13 March 2026
Pharmaceutical
Ratio Therapeutics, a US pharma company developing radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Colin Hayward as chief medical officer (CMO). 13 March 2026
Pharmaceutical
Eli Lilly has announced plans to invest a total of $3 billion over the next 10 years to comprehensively expand its supply chain capacity in China. 12 March 2026
Pharmaceutical
Swiss neurotechnology firm MindMaze Therapeutics has appointed healthtech executive Zach Henderson as chief executive, as the company looks to expand adoption of its FDA-cleared neurorestorative platform in the USA. 12 March 2026
Pharmaceutical
US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million. The funding was led by Frazier Life Sciences and includes participation from existing investors Atlas Venture, Access Industries and Canaan Partners. 12 March 2026
Biotechnology
TolerogenixX, a biopharma developing personalized cell therapies to induce sustained immune tolerance in organ transplantation and autoimmune diseases, has achieved an important milestone with its lead cell therapy candidate, MIC-Lx. 11 March 2026
Latest In Brief for Novartis
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze